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Abstract: Insulin resistance (IR) is defined as a lower-than-expected response to insulin action from 
target tissues, leading to the development of type 2 diabetes through the impairment of both glu-
cose and lipid metabolism. IR is a common condition in subjects with nonalcoholic fatty liver dis-
ease (NAFLD) and is considered one of the main factors involved in the pathogenesis of nonalco-
holic steatohepatitis (NASH) and in the progression of liver disease. The liver, the adipose tissue 
and the skeletal muscle are major contributors for the development and worsening of IR. In this 
review, we discuss the sites and mechanisms of insulin action and the IR-related impairment along 
the spectrum of NAFLD, from simple steatosis to progressive NASH and cirrhosis.  
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1. Introduction 
Insulin resistance (IR) is defined as a lower-than-expected response to insulin action 
from target tissues, resulting in the impairment of both glucose and lipid metabolism at 
different levels and predisposing to the development of type 2 diabetes mellitus (T2DM) 
[1]. IR is a metabolic abnormality often observed in subjects with nonalcoholic fatty liver 
disease (NAFLD), and it has been considered one of the major determinants in the 
pathogenesis of nonalcoholic steatohepatitis (NASH) as well as in the progression of liver 
disease. The main sites involved in IR are the skeletal muscle, the liver and the adipose 
tissue; the active crosstalk between these organs is likely to be a major contributor to the 
development of NAFLD and NASH. 
In this review, we discuss the sites and mechanisms of insulin action and IR-related 
impairment along the spectrum of NAFLD, from simple steatosis to progressive NASH 
and cirrhosis.  
2. Metabolic Effects of Insulin 
Insulin is synthesized in pancreatic β-cells of the Langerhans islets as a single chain 
precursor, pre-proinsulin; subsequently, the removal of a signal peptide in the endo-
plasmic reticulum generates proinsulin. Proinsulin consists of three domains: an ami-
no-terminal B chain, a carboxy-terminal A chain and a connecting peptide (CP) in the 
middle. Within the endoplasmic reticulum, proinsulin is exposed to the action of specific 
endopeptidases that cleave the CP, generating the mature form of insulin. In the post-
prandial state, when the beta cells are stimulated, insulin is released by exocytosis into 
the bloodstream, where it maintains blood glucose homeostasis by promoting glucose 
uptake in several tissues, favoring anabolic metabolism. 
The biological action of insulin takes place through the interaction between insulin 
and its specific receptor. The insulin receptor is a glycosylated tetramer consisting of two 
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extracellular subunits (alpha) and two transmembrane subunits (beta) with tyrosine ki-
nase activity. Insulin binding promotes the autophosphorylation of the receptor and 
subsequent tyrosine phosphorylation of insulin receptor substrate (IRS) proteins (IRS-1 
and IRS-2), which initiate a cascade of events and promote anabolic effects in several 
organs and tissues [1]. 
Sites and Mechanisms of Insulin Action and Insulin Resistance 
Several factors, such as hyperinsulinemia and hyperglycemia, together with in-
creased free fatty acid (FFA) concentrations and proinflammatory cytokine levels, may 
alter insulin signaling in different tissues. These metabolic alterations, which lead to the 
development and worsening of IR, are common in obese subjects as well as in patients 
with NAFLD and predispose to the development of T2DM. Despite the primary site of IR 
being questionable, a growing body of evidence indicates that the periphery plays an 
important role in the onset of IR, in addition to hepatic steatosis, which exacerbates it [2]. 
In the skeletal muscle of healthy subjects, insulin activates intracellular signaling through 
the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB)/mammalian target of 
rapamycin (mTOR) pathway, thus promoting the expression and translocation of glucose 
transporter type 4 (GLUT4) from the cytoplasm to the cell membrane. After a glucose 
load, the absorbed glucose is phosphorylated to glucose-6-phosphate (G6P) by the en-
zyme hexokinase, and, in this form, it can be used in either the glycolytic or tricarboxylic 
acid (TCA) pathway, in order to produce energy in the form of adenosine triphosphate 
(ATP); otherwise, it can be stored as glycogen through glycogen synthesis. In healthy 
subjects, ~75% of the disposed muscle glucose is converted into glycogen, while 20–25% 
enters the glycolytic pathway [3]. Moreover, in the skeletal muscle, insulin promotes 
amino acid (AA) uptake, increases the rate of protein synthesis, and decreases the rate of 
protein degradation. In the insulin-resistant condition, insulin-mediated glucose uptake 
in the postprandial state is impaired [3]. In T2DM, the reduction of glycogen synthase 
activity is an early defect, leading to deranged glycogen synthesis, followed by reduced 
glucose oxidation [4]. Diabetic patients also show an impaired phosphorylation of IRS-1, 
leading to a reduced translocation of GLUT4 and a decreased glucose uptake by the 
muscle [5,6]. IR is associated with a low-grade chronic inflammatory state, which is ob-
served in obese, in diabetic and in NAFLD subjects [7]. Inflammation in myocytes may 
promote muscle IR through the expression of proinflammatory cytokines such as tumor 
necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β), which in turn activate the 
protein kinase C (PKC), the c-Jun N-terminal kinase (JNK) and the nuclear factor kap-
pa-light-chain-enhancer of activated B cells (IKK/NF-kB) pathways, thus disrupting in-
sulin signaling [7] (Figure 1). 




Figure 1. Sites and mechanisms of insulin resistance. Inflamed adipose tissue releases several proinflammatory cytokines 
such as TNF-α, IL6 and IL-1β,which inhibit the insulin receptor, impairing insulin signaling. In the insulin-resistant 
condition, the inadequate suppression of lipolysis (due to the impaired inhibition of PKA) promotes the efflux of free 
fatty acids (FFAs) from the adipose tissue, which reach the liver and the muscle, where they contribute to ectopic fat ac-
cumulation. Abbreviations. Adipose tissue insulin resistance (AT-IR); adipose tissue macrophages (AT-M); protein kinase 
B (Akt); branched-chain amino acids (BCAA); ceramides (CER); DAGs (diacylglycerols); cyclic adenosine monophos-
phate (cAMP); de novo lipogenesis (DNL); FFAs (free fatty acids); factor forkhead box 01 (FOXO1); glycogen phosphor-
ylase (GlyPase); glucose transporter type 4 (GLUT4); interleukin 1-beta (IL-1β); interleukin 6 (IL-6); insulin receptor 
(IRec); IRS1/2 (insulin receptor substrate 1/2); protein kinase A (PKA); mammalian target of rapamycin (mTOR); protein 
kinase C isoform ε (PKCε); phosphodiesterase (PDE); peroxisome proliferator-activated receptor gamma co-activator 1α 
(PGC-1α); phosphatidylinositol 3 kinase (PI3K); ribosomal protein S6 kinase β1 (S6Kβ1); sterol regulatory ele-
ment-binding protein-1c (SREBP-1c); tumor necrosis factor alpha (TNF-α). 
In the liver, endogenous glucose production is not inhibited due to IR, and glycogen 
lysis is active, increasing blood glucose levels. The overload of toxic lipids such as DAGs 
and ceramides activates the PKCεpathway, disrupting insulin signaling and promoting 
gluconeogenesis through the regulation of FOXO1. Moreover, de novo lipogenesis (DNL) 
is increased by the regulation of the mTOR and SREBP-1c pathways; branched-chain 
amino acids (BCAA) can directly activate mTOR, enhancing DNL. In the skeletal muscle, 
IR impairs the release of GLUT4 from intracellular vesicles to the cell membrane, de-
creasing glucose uptake. BCAA can activate the mTOR and PGC-1α pathways, affecting 
the insulin signaling cascade. Similarly, proinflammatory cytokines activate an inflam-
matory cascade through the PKC/JNK/IKK-NF-kB pathway, disrupting insulin signaling. 
Another important cause of IR is the increased amount of FFAs caused by the im-
paired lipolysis in the adipose tissue. In studies performed both in animal models and in 
humans, lipid infusion increases diacylglycerol (DAG) levels and PKC signaling, leading 
to a defective activation of the IRS-1/Akt pathway in the skeletal muscle [8]. An increased 
lipid content in the myocytes has been observed in type 2 diabetic patients as well as in 
their offspring. Diacylglycerols, ceramides and long-chain acyl-CoA are directly involved 
in the development of IR by the inhibition of the Akt pathway, leading to a defective 
glucose uptake [9–12]. Recently, Luukkonen P.K. et al. demonstrated that a diet enriched 
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in saturated FFAs increases ceramide levels in overweight nondiabetic subjects, leading 
to IR by disrupting insulin signaling [13]. 
Insulin also exerts its activity through branched-chain amino acids (BCAA) (espe-
cially leucine), leading to opposite responses: on one hand, leucine can potentiate insulin 
action through the phosphorylation of IRS and Akt/mTOR [14,15]; on the other hand, 
high leucine levels can activate mTOR through the ribosomal protein S6 kinase β1 
(S6Kβ1), leading to an impairment of insulin signaling, thus promoting IR [16,17]. BCAA 
can also impair mitochondrial function through the downregulation of peroxisome pro-
liferator-activated receptor gamma co-activator 1α (PGC-1α)-responsive genes, involved 
in mitochondrial oxidative phosphorylation [18]. Specifically, PGC-1α enhances valine 
catabolism, leading to the production of the intermediate 3-hydroxyisobuterate (3-BOH) 
that, in turn, acts as a paracrine factor, reducing insulin sensitivity by inhibiting Akt 
phosphorylation in C2C12 myotubes [18]. Of note, acylcarnitine, a product of the in-
complete oxidation of both BCAA and free fatty acids (FFAs), can induce oxidative stress, 
thus interfering with insulin signaling [19,20]. 
In the liver, glucose can be 1. oxidized for energy in the glycolytic pathway, 2. me-
tabolized to CO2 and H2O through the tricarboxylic acid (TCA) pathway or 3. stored as 
glycogen via glycogen synthesis. Most of the glucose (about 88%) enters the third meta-
bolic pathway; it is phosphorylated to G6P and contributes to the hepatic glycogen de-
pots [21]. The amount of glycogen in the liver is higher compared to that in the skeletal 
muscle [21]. During fasting, glucose homeostasis is maintained by hepatic glucose pro-
duction (HGP), which has two main components: glycogen lysis and gluconeogenesis. 
The lysis of glycogen is regulated by the enzyme glycogen phosphorylase through the 
phosphorylation and activation of protein kinase A (PKA) and by the enzyme phos-
phoglucomutase, which regulates the release of glucose-1-phosphate from the glycogen 
molecule and its conversion to G6P. After a glucose load, the activation of PKB in the 
insulin receptor cascade leads to the inhibition of gluconeogenic enzymes via the phos-
phorylation of FoxO1 and to the inactivation of the enzyme glycogen synthase kinase 3β 
(GSK3β), which regulates glycogen synthesis [22,23]. When glycogen depots gradually 
decrease, gluconeogenesis becomes the most important source of glucose [24]. Glucone-
ogenesis is the synthesis of glucose from noncarbohydrate carbon substrates such as 
lactate, pyruvate or alanine. It is activated by the induction of the enzymes pyruvate 
carboxylase (PK) and phosphoenolpyruvate carboxykinase (PEPCK); the latter is inhib-
ited by insulin through Akt/transcription factor forkhead box 01 (FoxO1) phosphoryla-
tion. Nuclear magnetic resonance (NMR) 13C spectroscopy combined with the infusion 
of labelled glucose tracers revealed that after 22, 46 and 64 h of fasting, gluconeogenesis 
significantly increases from 64% to 82% to 96% and is a major contributor to the HGP in 
healthy subjects [24]. 
The excess of glucose is converted into FFAs through the de novo lipogenesis (DNL) 
pathway, which is regulated by the transcriptional factors sterol regulatory ele-
ment-binding protein-1c (SREBP-1c) and carbohydrate response element binding protein 
(ChREBP) by the activation of the transcription of several genes involved in lipogenesis 
such as acetyl-CoA carboxylase, fatty acid synthetase, acetyl-CoA synthetase and 
ATP-citrate lyase [25,26]. Diabetic patients are characterized by a defect in glycogen 
synthesis, which contributes to the increased risk of hypoglycemia during night, and by a 
20-fold higher gluconeogenesis when compared to healthy subjects [27]. Several molec-
ular mechanisms play a role in the development of IR in the liver. The impairment of 
FOXO1 regulation contributes to the increase in gluconeogenesis in patients with T2DM 
through the increased synthesis of gluconeogenic enzymes [28]. The upregulation of 
FOXO1 in obese mice leads to IR; conversely, mice knocked out for FOXO-1 show an 
improvement in insulin sensitivity and normalization of glucose tolerance [29]. 
Recently, it has been reported that PGC-1α is able to affect IRS-1 and IRS-2 expres-
sion, impacting normal glucose homeostasis [30]. Mice fed with a high fat diet show an 
increase in hepatic DAG content, and DAG can activate PKCε, the primary PKC isoform 
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in the liver [31]. Accordingly, the ectopic lipid accumulation both in the liver and in the 
muscle, due to adipose tissue IR, leads to the activation of the DAG/PKCε axis in the 
liver, which in turn inhibits insulin signaling [32]. The association between DAG levels 
and IR in humans is controversial, and further studies are necessary to understand which 
lipid species could be considered a signature of IR-associated conditions [33,34]. 
The adipose tissue is the third major site of insulin action and influences both glu-
cose and lipid homeostasis by releasing adipokines, proinflammatory cytokines and 
FFAs. The most important role of insulin in the adipose tissue is to suppress lipolysis, a 
process in which triglycerides are hydrolyzed into glycerol and FFAs, in turn used to 
provide energy during fasting. Briefly, insulin activates the IRS/PI3K/Akt pathway, thus 
promoting the phosphorylation of phosphodiesterase 3B, which in turn converts cyclic 
adenosine monophosphate (cAMP) into 5’-AMP. The reduction in cAMP decreases the 
phosphorylation of PKA and reduces the lipolysis rate [35]. Insulin-stimulated glucose 
disposal in the adipose tissue is negligible when compared to that in the skeletal muscle, 
but FFAs that are released into the bloodstream impact glucose homeostasis, exacerbat-
ing muscle IR. 
The second metabolic pathway regulated by insulin in the adipose tissue is lipo-
genesis, which leads to the accumulation of triglycerides in the adipocytes [27]. Excess 
food intake and energy storage leads to hypertrophic and inflamed adipose tissue. Sev-
eral proinflammatory factors such as TNF-α, IL-6 and IL-1β are overexpressed in en-
larged adipocytes compared to smaller ones, linking hypertrophic obesity to IR [36,37]. 
TNF-α promotes the serine phosphorylation of IRS-1, decreasing its association with 
PI3K, thus disrupting insulin signaling [38] (Figure 1). In the IR condition, the activation 
of PKA by cAMP leads to the phosphorylation of hormone-sensitive lipase (HSL) and 
perilipin; the subsequent translocation of HSL from the cytosol to the lipid droplet sur-
face enhances lipolysis. The result of the impaired suppression of lipolysis is an increased 
release of FFAs and glycerol into the bloodstream and ectopic fat accumulation [38]. 
Among ectopic lipids, toxic species such as DAG and ceramides can disrupt insulin sig-
naling by inhibiting insulin receptor and Akt activation [39]. Adipose tissue IR has also 
been linked to mitochondrial dysfunction and mitophagy; decreased mitochondrial bio-
genesis and reduced mitochondrial oxidative protein content lead to a reduced oxidative 
capacity [40,41]. 
3. Insulin Resistance in Nonalcoholic Fatty Liver Disease 
3.1. Relation between Hepatic Steatosis and Insulin Resistance 
The association between NAFLD and IR has been widely investigated. The preva-
lence of IR is high in NAFLD and even higher in subjects with NASH compared to those 
with simple steatosis [42]; to date, IR is considered the main pathogenetic mechanism 
involved in the onset of NAFLD and its progression to NASH [43–45]. In the IR state, fat 
accumulation in the liver is caused by the impaired uptake, synthesis, export and oxida-
tion of FFAs. In NAFLD subjects, the amount of hepatic steatosis correlates with in-
creased plasma levels of FFAs due to the impaired suppression of lipolysis from the ad-
ipose tissue; subcutaneous adipose tissue represents a major source of intrahepatic fat 
(~62–82% of intrahepatic triglycerides). This mechanism is independent of obesity and 
diabetes, as it has also been demonstrated in nonobese, nondiabetic NAFLD patients; in 
the latter group, IR affects HGP, glucose disposal (glycogen synthesis and glucose oxi-
dation), lipolysis and lipid oxidation. Although visceral fat is not the main supplier of 
circulating FFAs, it represents the main source of inflammatory cytokines reaching the 
liver, as confirmed by the correlation between IL-6 and C-reactive protein levels in the 
portal vein [46,47]. 
In the insulin-resistant condition, the liver loses its ability to suppress HGP in re-
sponse to insulin and enhances DNL through the activation of the Notch signaling 
pathway [48]. This explains, on one hand, the increase in DNL that, in NAFLD patients, is 
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5-fold higher when compared to that in healthy subjects (26 vs. 5%, respectively) and, on 
the other hand, the predisposition to diabetes in subjects with NAFLD [48]. 
3.2. Insulin Resistance in the Progression from Simple Steatosis to Nonalcoholic Steatohepatitis 
and Fibrosis 
The development of NASH has been linked to a variety of factors, including nutrient 
intake, endocrine derangements (insulin, leptin, adiponectin and ghrelin), alterations in 
gut microbiota (endotoxemia) and epigenetic factors, possibly acting on a genetic pre-
disposition [49]. Unfortunately, the molecular mechanisms leading to NASH and fibrosis 
development have not been fully elucidated yet. Hepatic triglyceride depositions into li-
pid droplets are considered a sort of inert storage; notwithstanding this, excessive lipid 
overload may enhance lipid oxidation and reactive oxygen species (ROS) release, making 
the liver susceptible to the action of proinflammatory factors. In obese and in diabetic 
patients, ROS levels correlate with the C-reactive protein concentration as well as fi-
brinogen levels, suggesting a subclinical proinflammatory state [49,50]. In NAFLD, the 
saturated FFA palmitate seems to play an important role in the progression of liver 
damage; it is synthesized in the DNL pathway and is able to trigger fibrogenesis in the 
liver through the activation of hepatic macrophages [51]. 
Several factors are able to mediate liver damage in patients with NAFLD; some of 
these are synthesized by the liver, while others are released by the adipose tissue and 
exert their effects in a paracrine way [52]. The liver is the main source of selenoprotein P 
(SeP), a selenium carrier protein with antioxidant properties. SeP is regulated by hyper-
glycemia and is able to induce IR, disrupting glucose homeostasis, thus favoring the de-
velopment of T2DM [52]. Recently, we found that circulating SeP increases according to 
the degree of hepatic steatosis and to the stage of fibrosis in nondiabetic patients with 
NAFLD, suggesting its potential role in the onset of NASH and progression to fibrosis 
[53]. 
Leptin is a peptide hormone that is released by adipocytes and plays a role in the 
regulation of food intake and bodyweight. In the setting of NAFLD, leptin may be ex-
pressed by activated hepatic stellate cells (HSCs) and by Kupffer cells (KCs), contributing 
to hepatic fibrogenesis, thus enhancing HSC signal transduction [49,54]. Specifically, 
leptin stimulates the transcriptional activation of both the α1(I) and α2(I) fibrils, which 
are major components of dense extracellular matrix (ECM). Furthermore, leptin promotes 
the synthesis of the matrix metalloproteinase-2 (MMP-2), tissue inhibitor matrix metal-
loproteinase 1 (TIMP-1), TIMP-2, and alpha-smooth muscle actin (α-SMA) transcripts, all 
involved in the pathogenesis of liver fibrosis [55,56]. Finally, leptin protects HSCs against 
apoptosis [55]. Although higher leptin levels were found in patients with NAFLD com-
pared to healthy controls, its role in the pathogenesis of NASH has not been fully eluci-
dated. 
Insulin-like growth factor 1 (IGF-1) is a hormone very similar to insulin in its mo-
lecular structure. IGF-1 is expressed primarily by the liver under the control of growth 
hormone, and it circulates linked to IGF-binding protein 3 (IGFBP-3). IGF-1 is involved in 
hepatocyte differentiation, proliferation and apoptosis [57]. A recent meta-analysis 
showed that IGF-1 levels are reduced in NAFLD patients compared to healthy controls, 
suggesting a potential role as a therapeutic target [58]. Moreover, Hagstrom et al. found 
low IGF-1 levels in patients with severe fibrosis (F ≥ 3) compared to those with ab-
sent/mild fibrosis [59]. Even though the molecular mechanisms linking IGF-1 and the 
progression of liver damage in the setting of NAFLD have not been elucidated yet, recent 
data describe a novel role of IGF-1 in regulating stress-induced hepatocyte premature 
senescence in liver fibrosis. Specifically, IGF-1 is able to attenuate the oxidative 
stress-induced premature senescence of hepatocytes in mice through the inhibition of the 
interaction between nuclear p53 and progerin, a truncated version of the lamin A protein, 
improving hepatic steatosis and fibrogenesis [60]. 
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The liver is the main target for adiponectin, the most abundant adipocytokine syn-
thesized by the adipose tissue [61]. Low adiponectin levels are associated with steatosis, 
inflammation and fibrosis in the liver [61]. Specifically, circulating adiponectin decreases 
in obese subjects as well as in fibrotic patients with NAFLD. Adiponectin exerts an anti-
fibrotic action by reducing HSC activation and proliferation; in addition, it favors matrix 
degradation, reducing the molecular ratio of MMP-1 to TIMP-1, antagonizing lep-
tin-mediated signaling in hepatic fibrogenesis [62]. This potent profibrogenic effect of 
leptin may contribute to the endothelial alteration of hepatic sinusoids, whose fenestra-
tions are progressively replaced by an organized basement membrane. This process, 
known as the “capillarization” of hepatic sinusoids, is one of the major parenchymal al-
terations that drive the liver to an architecture causing portal hypertension [63,64]. 
In the past few years, genome-wide association studies have led to the identification 
of several genes related to NAFLD, NASH, and their complications including hepato-
cellular carcinoma (HCC). In 2008, Romeo et al. [65] described a single-nucleotide poly-
morphism (SNP) in the patatin-like phospholipase domain-containing 3 (PNPLA3) gene, 
which encodes the triglyceride lipase adiponutrin and strongly affects fat accumulation 
in the liver through mechanisms independent of IR. The PNPLA3 rs738409 (G) risk allele, 
found in ~40% of the European population, can also increase, threefold, the risk of pro-
gression to NASH and, most importantly, twelve-fold, the risk of developing HCC [66]. 
In subsequent years, other SNPs have been associated with increased hepatic fat 
accumulation and, thus, the progression of liver disease. The most important genetic 
variants are the rs58542926 C > T located in the transmembrane 6 superfamily member 2 
(TM6SF2) gene and the rs641738 C > T located in the membrane-bound 
O-acyl-transferase domain-containing 7 (MBOAT7) gene, which favor hepatic fat accu-
mulation in intracellular lipid droplets via different mechanisms, increasing the suscep-
tibility to inflammation, NASH and fibrosis [67]. 
4. Insulin Resistance in Advanced Liver Disease 
4.1. Insulin Resistance and Cirrhosis 
Liver cirrhosis represents the final stage of the natural history of any chronic liver 
disease. The parenchymal structure becomes progressively subverted by regenerative 
nodules and fibrosis septa. Its course is indolent, until portal hypertension develops from 
persistent splanchnic hemodynamic changes and the disruption of intrahepatic sinus-
oids. Portal hypertension paves the way to systemic damage and the onset of clinical 
manifestations of liver disease. In addition, the presence of cirrhosis itself constitutes the 
proinflammatory ground where hepatocellular carcinoma (HCC) can develop, along 
with etiology-driven additional damage. 
In patients with NAFLD-related cirrhosis, IR represents the primum movens of the 
chronic liver disease. On the other hand, it is known that all cirrhotic patients are prone to 
being insulin resistant, irrespective of the etiology, because cirrhosis itself may lead to 
alterations in glucose metabolism [68–70]. Nevertheless, IR as assessed by the homeosta-
sis model of assessment of insulin resistance (HOMA-IR) index may differ according to 
the cause of cirrhosis, being higher in NAFLD- and HCV-related chronic hepatitis, com-
pared to alcohol- and HBV-related disease [71]. Specific hepatokines can contribute to IR, 
such as selenoprotein-P, which has a direct influence on insulin action in skeletal muscle 
in NAFLD subjects [72]. Furthermore, cytokines secreted by the liver, as a consequence of 
the persistent necroinflammatory activity, such as TNF-α and IL-6, can also induce IR 
[73]. In cirrhotic patients, multiple distortions are involved in the onset of IR (Figure 2). 
 




Figure 2. Crosstalk between the cirrhotic liver and peripheral tissues in determining insulin resistance. Abbreviations. 
Advanced glycation end product (AGE); hypoxia-inducible factor 1-alpha (HIF-1α); interleukin-6 (IL-6); lipopolysaccha-
ride (LPS); tumor necrosis factor-alpha (TNF-α). 
In cirrhosis, impaired hepatocyte functionality and portal hypertension cause re-
duced insulin extraction, with subsequent hyperinsulinemia. In addition, glucagon is not 
properly metabolized, with persistent hyperglycemia. The cirrhosis-related chronic in-
flammatory state worsens insulin resistance by the secretion of cytokines (TNF-α and 
IL-6) and by enhancing a persistent hypoxic state, with the activation of HIF-1α. In re-
turn, the increased insulinemia contributes to sinusoid capillarization, favoring portal 
hypertension. The cirrhosis-induced hypercatabolic condition and congestive enteropa-
thy cause hyperammonemia and impaired gut permeability, with subsequent endotox-
emia and the activation of Toll-like receptors. These factors directly impact insulin sensi-
tivity, but also skeletal muscle activity, leading to sarcopenia and fat infiltration (my-
osteatosis), with reduced glycogen synthesis. Advanced glycation end products (AGEs) 
are not properly metabolized by the liver, with increased toxic damage to the pancreas. 
Finally, all the derangements impact the pancreas, where oxidative stress and glucose 
toxicity cause progressive damage to beta cells, whose impairment is crucial for devel-
oping overt diabetes. 
The augmented blood levels of insulin in end-stage liver disease are an effect of liver 
function impairment. Moreover, portal hypertension is thought to be another crucial 
driver of hyperinsulinemia. Due to the parenchymal alterations in advanced cirrhosis, 
the splanchnic blood flow cannot be properly conveyed throughout the liver. Hence, the 
blood is pumped in secondary small vessels that drive the flow from the portal vein to 
the systemic circulation. These vessels constitute the so-called “portosystemic shunts” 
that are responsible for conveying metabolites inside the systemic circulation, bypassing 
hepatocyte extraction. Likewise, high levels of insulin, coming from the splanchnic cir-
culation, are not properly metabolized inside the liver and directly cause systemic hy-
perinsulinemia. 
The two counterparts work in parallel and with a synergic effect. In mouse models 
undergoing partial hepatectomy, insulin levels dramatically increase [74], even in the 
absence of significant portal hypertension; when portosystemic shunts are suppressed in 
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advanced liver disease, insulin clearance is ameliorated, suggesting a role of portal hy-
pertension in determining IR [75]. Similarly, contra-insulin hormones, such as glucagon, 
are not adequately metabolized by damaged hepatocytes and persistently stimulate 
glucose production. 
One of the most typical features of cirrhotic patients is malnutrition, due to both 
decreased nutrient intake and diminished protein synthesis in a persistent catabolic state. 
The reduction of liver glycogen leads to an accelerated fasting condition and a parallel 
increase in gluconeogenesis, mainly driven by amino acids from muscle proteins. All 
these factors inevitably lead to skeletal muscle wasting and sarcopenia, a well-known 
hallmark of cirrhosis associated with poor prognosis [76]. 
Increased levels of ammonia are a common finding in advanced liver disease, de-
pending on both impaired hepatocyte metabolism and portosystemic shunts. Hyper-
ammonemia directly affects skeletal muscle, stimulating the synthesis of myostatin. 
Myostatin seems to be crucial in cirrhosis-induced peripheral IR, as it depletes protein 
mass and induces fat accumulation inside the muscle. This phenomenon, known as 
“myosteatosis”, can downregulate muscle insulin receptor, leading to impaired glucose 
transport and glycogen synthesis [77,78]. 
The transient bacteremia in cirrhosis is due to the congestion of the small and large 
intestine in portal hypertension with altered permeability. A impaired immune response 
facilitates pathogenic strain proliferation [79] and the translocation of gut-derived endo-
toxins (mainly lipopolysaccharide), leading to the activation of Toll-like receptors, in-
volved in the pathogenesis of IR [80]. 
The deterioration of beta-cell function is mainly driven by chronic hyperglycemia, 
which causes toxic damage to the pancreatic islets of Langerhans [81–83]. This process is 
enhanced by the accumulation of advanced glycation end products (AGEs), by inducing 
oxidative stress. The liver is involved in the clearance of AGEs; in cirrhosis, these prod-
ucts may not be properly metabolized, thus boosting oxidative stress in beta cells [84]. 
One further worsening factor is constituted by the systemic low-grade hypoxia induced 
by cirrhosis and related to the severity of the disease [85]. Chronic liver tissue injury and 
the persistence of alterations in normal intrahepatic vascular perfusion are responsible 
for the hypoxic parenchymal microenvironment. Moreover, the ineffective liver clearance 
of vasodilating agents (e.g., nitric oxide), coming from the splanchnic circulation, may 
affect pulmonary regulatory function, resulting in diffusion–perfusion defects and per-
sistent capillary dilation, contributing to systemic hypoxemia. 
The subsequent activation of hypoxia-inducible factors (mainly HIF-1α) can trigger 
an inflammatory response in beta cells, as well as directly altering glucose metabolism 
[86], contributing to the development of overt diabetes. 
4.2. Hepatogenous Diabetes 
About 80% of cirrhotic patients become glucose intolerant, and nearly 20% of them 
develop frank diabetes [87]. In 1906, diabetes arising in cirrhosis was renamed “hepato-
genous diabetes” to distinguish this entity from type 2 diabetes [88]. Hepatogenous dia-
betes shares neither the same risk factors of type 2 diabetes (family history, obesity and 
older age) nor the same complications (mainly micro- and macrovascular damage) [89]. 
The onset of hepatogenous diabetes is relatively more rapid compared to that of type 2 
diabetes, as up to 20% of cirrhotic patients develop hyperglycemia within 5 years [90,91]. 
This form of diabetes often presents with normal glucose levels (due to impaired glucose 
metabolism) and normal glycated hemoglobin (due to the reduced lifespan of erythro-
cytes) [92,93]. As a result, the presence of diabetes can only be suspected based on high 
glycated hemoglobin levels in a small proportion of patients. Interestingly, fructosamine 
measurement, which reflects the glycemic status over 2–4 weeks, seems to be more ac-
curate for the evaluation of glycemic control in this population [94]. 
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In hepatogenous diabetes, the specific pathophysiological pathways include im-
paired insulin sensitivity, which represents an early event, and subsequently beta-cell 
dysfunction, essential for the transition to frank diabetes [88]. 
The interplay between peripheral tissues and the liver is crucial in determining the 
phenotype. One seminal Australian study conducted in 1980 found that the liver pro-
duction of endogenous glucose was markedly reduced in cirrhotic patients, even in those 
without diabetes, as a consequence of glucose intolerance driven by peripheral (muscle) 
IR, while the liver was hypersensitive to insulin action [95]. One subsequent study from 
Petrides et al. demonstrated a reduction of glycogen synthesis in the muscle [96]. As cir-
rhosis progresses, there is no further worsening of IR: in one study conducted in 2016 on 
300 pretransplant patients, the proportions of individuals with diabetes, with respect to 
those without diabetes or with prediabetes, did not differ among the different grades of 
cirrhosis severity [97]. 
Hepatogenous diabetes does not affect short-term survival but seems to be associ-
ated with higher mortality in long-term periods [98–100], mainly driven by portal hy-
pertension rather than the micro-/macrovascular complications of diabetes. Indeed, few 
patients develop retinopathy, as well as cardiovascular events [89]. 
Different longitudinal studies conducted on cirrhotic patients have assessed the role 
of diabetes in reducing transplantation-free survival (Table 1), with discordant results. 
Table 1. Longitudinal studies conducted on cirrhotic patients evaluating the impact of diabetes on 










Bianchi et al. [98] 1984 382 * 37 death (HR = 2.30, p = 0.019) 
Moreau et al. [99] 2004 75 * 18 death (HR = 2.20, p = 0.03) 
Sangiovanni et al. [101] 2006 214 204 not significant 
Berman et al. [102] 2011 447 * 3 not significant 
Quintana et al. [100] 2011 110 30 death (OR = 3.30, p = 0.007) ** 
Elkrief et al. [103] 2014 348 * 60 ascites (OR = 1.70, p = 0.05) 
    bacterial infections (OR = 3.02, p = 0.001) 
    HE (OR = 6.55, p < 0.001) 
    HCC (OR = 1.93, p = 0.016) 
    death (HR = 1.33, p = 0.027) 
Abbreviations. Hepatocellular carcinoma (HCC); hepatic encephalopathy (HE); hazard ratio (HR); 
odds ratio (OR). 
In one French study including 348 decompensated patients, diabetes was inde-
pendently correlated with worse survival in patients with better liver functionality, as 
expressed by a Model for End-stage Liver Disease (MELD) score lower than 10 [103]. 
However, another large study conducted for a median time of 17 years challenged the 
independent impact of diabetes on survival [101]. 
Nonetheless, diabetes can impact the onset and severity of specific liver-related 
complications. Ascites seems to occur more frequently when diabetes is present, irre-
spectively of residual liver functionality [104]. This may be related to the microvascular 
alterations caused by diabetes that occur in the kidney and in the liver, facilitating the 
onset of portal hypertension [75,105]. Similarly, diabetes has been associated with hepatic 
encephalopathy, independently of MELD score [106]. Autonomic neuropathy and im-
paired intestinal motility may accelerate the onset of small intestinal bacterial over-
growth and bacterial translocation, a major causal factor of encephalopathy. Interesting-
ly, the administration of acarbose in patients with cirrhosis and diabetes significantly 
reduced blood ammonia levels, improving psychometric tests for minimal encephalo-
pathy [107]. Diabetes acts in synergy with cirrhosis in conferring a higher risk of bacterial 
infections, as emerged from studies conducted on patients undergoing liver transplanta-
tion [108]. 
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The impact of diabetes on HCC is complex. In one large meta-analysis of 28 pro-
spective studies including cirrhotic patients, diabetes was associated with an increased 
incidence of HCC and HCC-related mortality. Pre-existent diabetes, rather than hepato-
genous diabetes, appeared to have a well-defined impact on the onset of HCC [109]. This 
is crucial when considering HCC in NAFLD-related cirrhosis, where metabolic de-
rangements are the main drivers of both liver damage and carcinogenesis, even in 
noncirrhotic NAFLD patients [110]. 
Liver transplantation may improve or reverse diabetes, but this positive effect is 
counterbalanced by the susceptibility to developing diabetes due to immunosuppressive 
therapy and changes in nutritional habits [111–113]. Some studies have reported a suc-
cessful regression of pre-existent diabetes in up to two thirds of cases [114], whereas 
other authors have found a substantial lack of improvement at one-year follow-ups, as 
shown by a markedly low insulin response during the oral glucose tolerance test (OGTT) 
[113]. Abnormalities in glucose tolerance seem to persist after liver transplantation even 
in patients with apparently normal glucose profiles [115]. Grancini et al. proved the cen-
tral role of beta-cell functionality in explaining such discrepancies. In fact, rescued be-
ta-cell functionality after transplantation allowed an increase in insulin bioavailability, 
playing a central role in favoring diabetes regression [116]. On the other hand, beta cells’ 
irreversible secretory defects are mainly responsible for the inefficacy of liver transplan-
tation regarding the improvement of diabetes [116]. 
5. Conclusions 
Insulin resistance is a common feature in NAFLD subjects, and it is considered one 
of the most important “hits” driving the progression from simple steatosis to NASH 
along with lifestyle, genetic predisposition and gut microbiota changes. In the liver, lipid 
overload enhances oxidative stress, leading to mitochondrial dysfunction, which in turn 
exacerbates inflammation and activates inflammatory pathways. 
Insulin resistance is also a common finding in cirrhotic patients, irrespective of eti-
ology. Glucose metabolism disturbances are not easily detected, due to multiple systemic 
perturbations. Careful monitoring is required, particularly of beta-cell residual function-
ality, which is crucial for the transition to overt diabetes and potential reversal after liver 
transplantation. Frank diabetes should be actively managed, as it may impact long-term 
survival and the severity of liver-related events. 
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